Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer
Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new treatment for patients with platinum-resistant ovarian cancer.

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data for IMNN-001 in advanced ovarian cancer.